Lack of reliability of nanotechnology in the of free plasma DNA in samples of patients with prostate cancer

Table 1 Plasmatic DNA (pDNA) assessed by nanotechnology and respective differences

*SAMPLE*		*[ ] μg/mL*		*SAMPLE*		*[ ] μg/mL*
NUMBER	[ ] pDNA 1	[ ] pDNA 2	DIFFERENCE	NUMBER	[ ] pDNA 1	[ ] pDNA 2	DIFFERENCE
1	59	51	8	27	42.5	31	*11.5*
2	130.5	92.5	38	28	50	47	3
3	37	36	1	29	51.5	50.5	1
4	100.5	76	*24.5*	30	132.5	132.5	0
5	26	25.5	*0.5*	31	65.5	56.5	9
6	129.5	133.5	4	32	84	101	17
7	142.5	146.5	4	33	161.5	150	*11.5*
8	74	59	15	34	37.5	20	*17.5*
9	59.5	41	*18.5*	35	97.5	82.5	15
10	70.5	63	*7.5*	36	121.5	150.5	29
11	52.5	43.5	9	37	55	52	3
12	71.5	64.5	7	38	136.5	131	*5.5*
13	67	65.5	*1.5*	39	128.5	102.5	26
14	88.5	72	*16.5*	40	36.5	28	*8.5*
15	85	78.5	*6.5*	41	90.5	72.5	18
16	98.5	88.5	10	42	109.9	105	*4.9*
17	49.5	48.5	1	43	197.5	197	*0.5*
18	128.5	154	*25.5*	44	133.5	130	*3.5*
19	61.5	49.5	12	45	46	45.5	*0.5*
20	80	59	21	46	56	49	7
21	71	68.5	*2.5*	47	71.5	57.5	14
22	140.5	140.5	0	48	80	79	1
23	159.5	167.5	8	49	99	75	24
24	30	24.5	*5.5*	50	116.5	134.5	18
25	72	60	12	51	47	45.5	*1.5*
26	187.5	172	*15.5*